Preclinical validation and phase i trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dntp synthesis in multiple myeloma

HIGHLIGHTS

• who: Yongsheng Xie from the Department of Hematology, Shanghai Tenth People`s Hospital, Tongji University School of Medicine, YanChang Road, Shanghai, China have published the article: Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma, in the Journal: (JOURNAL) of 12/09/2018
• what: The authors explored the efficacy of the novel RNR inhibitor 4-hydroxysalicylanilide (HDS) in myeloma cells and xenograft model. HDS also showed a favorable safety profile and demonstrated clinical activity against MM. Conclusions: the study provides a rationale for the clinical evaluation . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.